Helga Radner1, Kazuki Yoshida2, Ihsane Hmamouchi2, Maxime Dougados2, Josef S Smolen2, Daniel H Solomon2. 1. From the Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA; Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria; Mohammed V Souissi University, Faculty of Medicine, Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Rabat, Morocco; Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique Hôpitaux de Paris, EULAR center of excellence, INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité, Paris, France.H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna; K. Yoshida, MD, MPH, Department of Epidemiology, Harvard School of Public Health; I. Hmamouchi, MD, PhD, Mohammed V Souissi University, Faculty of Medicine, Laboratory of Biostatistics, LBRCE; M. Dougados, MD, Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique Hôpitaux de Paris, EULAR center of excellence, INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; J.S. Smolen, MD, Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital. hradner@partners.org. 2. From the Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA; Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria; Mohammed V Souissi University, Faculty of Medicine, Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Rabat, Morocco; Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique Hôpitaux de Paris, EULAR center of excellence, INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité, Paris, France.H. Radner, MD, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna; K. Yoshida, MD, MPH, Department of Epidemiology, Harvard School of Public Health; I. Hmamouchi, MD, PhD, Mohammed V Souissi University, Faculty of Medicine, Laboratory of Biostatistics, LBRCE; M. Dougados, MD, Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique Hôpitaux de Paris, EULAR center of excellence, INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; J.S. Smolen, MD, Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital.
Abstract
OBJECTIVE: To describe the treatment profile of multimorbid patients with rheumatoid arthritis (RA) in contrast to patients with RA only. METHODS: COMORA (Comorbidities in Rheumatoid Arthritis) is a cross-sectional, international study assessing morbidities, outcomes, and treatment of patients with RA. Patients were grouped according to their multimorbidity profile assessed by a counted multimorbidity index (cMMI). Treatment for RA was categorized as use of biologic disease-modifying antirheumatic drugs (bDMARD), in particular tumor necrosis factor inhibitors (TNFi), synthetic DMARD (sDMARD) use only, nonsteroidal antiinflammatory drug (NSAID) use, and corticosteroid use. Logistic regression models were performed to determine the OR of bDMARD, TNFi, sDMARD, NSAID, or corticosteroid use based on a patient's cMMI and global region after adjusting for age, disease activity, disease duration, educational level, and previous DMARD therapy. RESULTS: Out of 3920 patients, 32.7% received bDMARD; 59.9% sDMARD only, 51.1% used concomitant NSAID, and 54.8% used corticosteroid. Regional differences were observed with the most frequent use of bDMARD in the United States (46.5%) and lowest in North Africa (9%). After adjusting for confounders in logistic regression, the OR for bDMARD use was reduced for each additional morbidity (OR 0.89, 95% CI 0.83-0.96). Similar results were found for TNFi (OR 0.91, 95% CI 0.84-0.99), whereas the OR for use of sDMARD was increased (1.13, 95% CI 1.05-1.22). No significant change of OR was found for NSAID or corticosteroid use. CONCLUSION: In this study, the odds of bDMARD use decreases 11% for each additional chronic morbid condition after adjustment for regional differences, disease activity, and other covariates.
OBJECTIVE: To describe the treatment profile of multimorbid patients with rheumatoid arthritis (RA) in contrast to patients with RA only. METHODS: COMORA (Comorbidities in Rheumatoid Arthritis) is a cross-sectional, international study assessing morbidities, outcomes, and treatment of patients with RA. Patients were grouped according to their multimorbidity profile assessed by a counted multimorbidity index (cMMI). Treatment for RA was categorized as use of biologic disease-modifying antirheumatic drugs (bDMARD), in particular tumor necrosis factor inhibitors (TNFi), synthetic DMARD (sDMARD) use only, nonsteroidal antiinflammatory drug (NSAID) use, and corticosteroid use. Logistic regression models were performed to determine the OR of bDMARD, TNFi, sDMARD, NSAID, or corticosteroid use based on a patient's cMMI and global region after adjusting for age, disease activity, disease duration, educational level, and previous DMARD therapy. RESULTS: Out of 3920 patients, 32.7% received bDMARD; 59.9% sDMARD only, 51.1% used concomitant NSAID, and 54.8% used corticosteroid. Regional differences were observed with the most frequent use of bDMARD in the United States (46.5%) and lowest in North Africa (9%). After adjusting for confounders in logistic regression, the OR for bDMARD use was reduced for each additional morbidity (OR 0.89, 95% CI 0.83-0.96). Similar results were found for TNFi (OR 0.91, 95% CI 0.84-0.99), whereas the OR for use of sDMARD was increased (1.13, 95% CI 1.05-1.22). No significant change of OR was found for NSAID or corticosteroid use. CONCLUSION: In this study, the odds of bDMARD use decreases 11% for each additional chronic morbid condition after adjustment for regional differences, disease activity, and other covariates.
Authors: Michael D George; Brian C Sauer; Chia-Chen Teng; Grant W Cannon; Bryant R England; Gail S Kerr; Ted R Mikuls; Joshua F Baker Journal: J Rheumatol Date: 2018-10-01 Impact factor: 4.666
Authors: Kazuki Yoshida; Tzu-Chieh Lin; Melissa Y Wei; Susan Malspeis; Su H Chu; Carlos A Camargo; Benjamin A Raby; Hyon K Choi; Sara K Tedeschi; Medha Barbhaiya; Bing Lu; Karen H Costenbader; Elizabeth W Karlson; Jeffrey A Sparks Journal: Arthritis Care Res (Hoboken) Date: 2021-02 Impact factor: 4.794
Authors: Bryant R England; Huifeng Yun; Lang Chen; Jared Vanderbleek; Kaleb Michaud; Ted R Mikuls; Jeffrey R Curtis Journal: Arthritis Care Res (Hoboken) Date: 2021-08-02 Impact factor: 5.178
Authors: Jeffrey R Curtis; Kevin Winthrop; Cathy O'Brien; Matladi N Ndlovu; Marc de Longueville; Boulos Haraoui Journal: Arthritis Res Ther Date: 2017-12-15 Impact factor: 5.156
Authors: Gustavo Nogueira Schincariol Vicente; Ivânio Alves Pereira; Gláucio Ricardo Werner de Castro; Licia Maria Henrique da Mota; Ana Paula Carnieletto; Dhara Giovanna Santin de Souza; Fabiana Oenning da Gama; Ana Beatriz Vargas Santos; Cleandro Pires de Albuquerque; Manoel Barros Bértolo; Paulo Louzada Júnior; Rina Dalva Neubarth Giorgi; Sebastião Cezar Radominski; Maria Fernanda Brandão Resende Guimarães; Karina Rossi Bonfiglioli; Maria de Fátima Lobato da Cunha Sauma; Claiton Viegas Brenol; Geraldo da Rocha Castelar Pinheiro Journal: Adv Rheumatol Date: 2021-06-25